polycystic ovary syndrome. Polycystic ovarian syndrome
Conditions
Interventions
Intervention 1: Intervention group: participants in the intervention group received 400 mg Date Palm Pollen once a day after lunch for 12 weeks. After characterizing Date Palm Pollen native to Abadan
Sponsors
Educational and Research Vice-Chancellor of Abadan University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 40 Years
Inclusion criteria
Inclusion criteria: To diagnose polycystic ovary syndrome according to the Rotterdam criteria, two of the following must be present: 1- Amenorrhea or reduced ovulation frequency Presence of hyperandrogenism based on clinical symptoms (hirsutism and male pattern hair loss) or laboratory (androgen increase) free or increased free androgen index) the presence of evidence of polycystic ovary in ultrasound.
Exclusion criteria
Exclusion criteria: People who use tobacco and alcohol. People suffering from chronic kidney, liver, lung diseases and chronic or acute inflammatory diseases (especially acute inflammation of the pancreas), thyroid dysfunction, heart valve disease, short bowel syndrome. Also, people with low ability of immune system (autoimmunity) are removed from the list of eligible people. These conditions are approved by the clinical consultant in the case of the studied subjects. Also, people who are allergic to medicine or placebo during the study. or taking chemotherapy drugs (tamoxifen) and corticosteroids, or drugs affecting blood sugar and lipids (insulin injections, statins, diuretics), antibiotics and vitamin supplements and omega 3, or suffering from one of the above-mentioned diseases Either they were admitted to the hospital or they had to change the dosage of the drugs they were taking, they were excluded from the study. To overcome the confounding factors, we use the general information questionnaire and the three-day record of people's food intake.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Alanine Aminotransferase(ALT). Timepoint: Measurement of biomarkers at the beginning of the study and after the twelfth week. Method of measurement: VT3000 device will be used to measure liver enzymes.;Aspartate Aminotransferase(AST). Timepoint: Measurement of biomarkers at the beginning of the study and after the twelfth week. Method of measurement: VT3000 device will be used to measure liver enzymes.;Alkaline Phosphatase(ALK-P). Timepoint: Measurement of biomarkers at the beginning of the study and after the twelfth week. Method of measurement: VT3000 device will be used to measure liver enzymes.;17a hydroxy-progesterone. Timepoint: Measurement of biomarkers at the beginning of the study and after the twelfth week. Method of measurement: LC/MS/MS device is used to measure steroid hormones.;Progesterone. Timepoint: Measurement of biomarkers at the beginning of the study and after the twelfth week. Method of measurement: LC/MS/MS device is used to measure steroid hormones.;Androstenedione. Timepoint: Measurement of biomarkers at the beginning of the study and after the twelfth week. Method of measurement: LC/MS/MS device is used to measure steroid hormones.;Estrogen. Timepoint: Measurement of biomarkers at the beginning of the study and after the twelfth week. Method of measurement: LC/MS/MS device is used to measure steroid hormones.;LH. Timepoint: Measurement of biomarkers at the beginning of the study and after the twelfth week. Method of measurement: LC/MS/MS device is used to measure steroid hormones.;CBC. Timepoint: Measurement of biomarkers at the beginning of the study and after the twelfth week. Method of measurement: Blood tests are performed by means of TB counter machines. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSamaneh Karimi
Abadan University of Medical Sciences
Outcome results
None listed